神奇製藥(600613.SH):神奇藥業擬申請2.5億元貸款
格隆匯12月25日丨神奇製藥(600613.SH)公佈,公司於2019年12月25日召開的第九屆董事會第十六次會議審議通過了《全資子公司神奇藥業申請銀行固定資產貸款的議案》,同意神奇藥業向興業銀行股份有限公司貴陽分行申請固定資產貸款。
子公司貴州神奇藥業有限公司正在進行沙文生產研發基地一期第二階段項目的投資建設。為保障沙文項目投資建設的順利進行,神奇藥業擬向銀行申請固定資產貸款,貸款金額2.5億元,貸款期限10年,貸款利率,不超過6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.